Shareholders' Equity and Redeemable Noncontrolling Interest |
9 Months Ended |
---|---|
Dec. 31, 2021 | |
Shareholders' Equity and Redeemable Noncontrolling Interest | Note 9—Shareholders’ Equity and Redeemable Noncontrolling Interest (A) RSL Common Stock In connection with the closing of the Business Combination, the Company adjusted its authorized share capital to equal 7,000,000,000 Roivant Common Shares, par value $ 41740141 per share. Each Roivant Common Share has the right to one vote. The holders of Roivant Common Shares are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the board of directors since the Company’s inception. On September 30, 2021 in connection with the closing of the Business Combination, RSL effected a 2.9262-for-1 (B) Consolidated Vant Equity Transaction Proteovant In July 2021, Proteovant Sciences, Inc. (“Proteovant”) collected the subscription receivable relating to the second $100.0 million payment due under a subscription agreement entered into with SK, Inc. (“SK”) in December 2020 pursuant to which SK agreed to make a $200.0 million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. |